Affiliation:
1. Dnipro State Agrarian and Economic University
2. State Biotechnological University
Abstract
Modern conditions of practical veterinary medicine require the use of effective and safe drugs. Along with the already known and common medicines, the search for new drugs which are harmless for the body and have the physiological direction of action is still required. In recent years, the attention to the use of phyto- and tissue-derived drugs increased. However, the problem of their use is insufficiently studied – many aspects of their clinical use require further development, expansion of the spectrum of used medicinal plants, study, and implementation into veterinary practice. Therefore, the purpose of this work was to develop a comprehensive vitamin-hormone drugs based on phyto- and tissue medicines for the treatment and prevention of reproductive abnormalities in animals. Based on the information on the etiopathogenesis of disorders of reproductive function indicators: homeostasis, reducing of the concentration of hormones (estrogen or progesterone), changes in the morphofunctional state of endocrine (pituitary, thyroid, and adrenal gland) and reproductive (ovaries) organs, the application of vitamin-hormone drugs in veterinary medicine is scientifically sound. Drugs in terms of pathogenetic therapy can optimise homeostasis, hormone concentrations, stimulate rehabilitation processes in the regulatory organs of reproductive function (pituitary, adrenal, and thyroid) and reproductive organs (ovaries), which, in turn, contributes to the normalisation of follicles which are a prerequisite for the full reproductive capacity of females. Vitamin-hormonal medicines of herbal and tissue origin were developed, with high efficiency for the treatment and prevention of reproductive pathologies of various species of animals, providing the stimulation of reproductive function (estrus signs) for therapy of females with gonadopathies (“Carafest”, “Caplaestrol” and “Caplagonìn”) and males (display of sexual reflexes and sperm quality) for reproductive activity dysfunction (“Carafand”), increase in the viability of the newborn (increasing the number of lambs and goatlings with satisfactory clinical condition with a high-growth potential, reduce in their morbidity and lethality), preventing the incidence of ìntra- and postnatal (labor hypofunction, diseases of post-labor period) pathology (“Carafest”, and “Caplaestrol”)
Publisher
Scientific Journals Publishing House
Reference64 articles.
1. Commission Directive 91/412/EEC laying down the principles and guidelines of good manufacturing practice for veterinary medicinal products. Official Journal L 228, 70-73. (1991, July). Retrieved from https://ec.europa. eu/health/sites/default/files/files/eudralex/vol-5/dir_1991_412/dir_1991_412_en.pdf.
2. Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products. Official Journal L 311, 1-66.
3. Kotsyumbas, I.Ya., Bisyuk, I.Yu., Horzheyev, V.M., Malyk, O.H., Zhyla, M.I., Kosenko, Yu.M., Chaykovska, O.I., Muzyka, V.P., Kotsyumbas, H.I., Patereha, I.P., Mazurkevych, A.Ya., Levytskyi, T.R., Brezvyn, O.M., Kushnir, I.M., Perih, Zh.M., & Ivaniv, M.I. (2013). Clinical studies of veterinary drugs and feed additives. Lviv: TOV Vydavnychyj dim “SAM”.
4. Polova, Zh.M., & Nazarkina, V.M. (2017). The analysis of economic availability of veterinary preparations in the segment of anti-mastitis medicines. Social Pharmacy in Health Care, 3(3), 35-41.
5. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance). (2004, March). Retrieved from https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32004R0726.